Management of active Crohn disease

JAMA

Volumn 309, Issue 20, 2013, Pages 2150-2158

  Cheifetz, Adam S ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BUDESONIDE; CALGRANULIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; LACTOFERRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MULTIVITAMIN; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB; VITAMIN D;

ABDOMINAL PAIN; ANUS FISTULA; BONE MARROW SUPPRESSION; COLON CANCER; COLONOSCOPY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DEMYELINATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG COST; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FAMILY HISTORY; HEART FAILURE; HUMAN; ILEITIS; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; INTESTINE BIOPSY; INTESTINE FLORA; LIVER TOXICITY; LUNG DISEASE; LYMPHOMA; MALE INFERTILITY; MEDICAL HISTORY; MELANOMA; MONOTHERAPY; NAUSEA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; PANCREATITIS; PARADOXICAL PSORIASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; SMALL INTESTINE OBSTRUCTION; SMOKING; TOXIC MEGACOLON; ULCERATIVE COLITIS; VOMITING;

EID: 84877987938     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.4466     Document Type: Review

References (79)

1. Kurata JH, Kantor-Fish S, Frankl H, et al. Crohn's disease among ethnic groups in a large health maintenance organization. Gastroenterology. 1992;102(6):1940-1948.
2. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993. Gastroenterology. 1998;114(6):1161-1168.
3. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8(4):244-250. (Pubitemid 34784976)
4. Singh B, Mortensen NJ, Jewell DP, George B. Perianal Crohn's disease. Br J Surg. 2004;91(7):801-814. (Pubitemid 38901346)
5. Vavricka SR, Spigaglia SM, Rogler G, et al Swiss IBD Cohort Study Group. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):496-505.
6. Silverstein MD, Lashner BA, Hanauer SB, et al. Cigarette smoking in Crohn's disease. Am J Gastroenterol. 1989;84(1):31-33. (Pubitemid 19042993)
7. Heresbach D, Alexandre JL, Branger B, et al ABERMAD (Association Bretonne d'Etude et de Recherche sur les Maladies de l'Appareil Digestif) . Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease. Gut. 2005;54(2):215-222.
8. Colombel JF, Solem CA, Sandborn WJ, et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography. Gut. 2006;55(11):1561-1567.
9. Zimmermann EM, Al-Hawary MM. MRI of the small bowel in patients with Crohn's disease. Curr Opin Gastroenterol. 2011;27(2):132-138.
10. Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy for small-bowel evaluation in Crohn's disease. Gastrointest Endosc. 2011;74(1):167-175.
11. Cheifetz AS, Kornbluth AA, Legnani P, et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol. 2006;101(10):2218-2222. (Pubitemid 44477546)
12. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. Gastroenterology. 1976;70(3):439-444.
13. Sands BE, Ooi CJ. A survey of methodological variation in the Crohn's disease activity index. Inflamm Bowel Dis. 2005;11(2):133-138. (Pubitemid 40711217)
14. Lahiff C, Safaie P, Awais A, et al. The Crohn's disease activity index (CDAI) is similarly elevated in patientswith Crohn's disease and in patientswith irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37(8):786-794.
15. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease. Can J Gastroenterol. 2005;19(suppl A):5-36.
16. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol. 1997;32(10):1005-1012.
17. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30(7):699-706.
18. Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):371-383.
19. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99(4):956-963. (Pubitemid 20338451)
20. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54(2):237-241. (Pubitemid 40139240)
21. Baert F, Moortgat L, Van Assche G, et al Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138(2):463-468.
22. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104(2):465-483.
23. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15(9):1295-1301.
24. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):935-939. (Pubitemid 43374542)
25. Feuerstein JD, Akbari M, Gifford AE, et al. Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelines. Aliment Pharmacol Ther. 2013;37(10):937-946.
26. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease. Clin Gastroenterol Hepatol. 2004;2(5):379-388.
27. Dignass A, Van Assche G, Lindsay JO, et al European Crohn's and Colitis Organisation. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management [published correction appears in J Crohns Colitis. 2010;4(3):353]. J Crohns Colitis. 2010;4(1):28-62.
28. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS). Gastroenterology. 1984;86(2):249-266.
29. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;(2):CD006792.
30. Thomsen OO, Cortot A, Jewell D, et al; International Budesonide- Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med. 1998;339(6):370-374. (Pubitemid 28363799)
31. Greenberg GR, Feagan BG, Martin F, et al Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. NEngl J Med. 1994;331(13):836-841. (Pubitemid 24289710)
32. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;(4):CD000545.
33. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;(1):CD000067.
34. Feagan BG, Rochon J, Fedorak RN, et al North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med. 1995;332(5):292-297.
35. Feagan BG, Fedorak RN, Irvine EJ, et al North American Crohn's Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med. 2000;342(22):1627- 1632. (Pubitemid 30341531)
36. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease. Lancet. 2002;359(9317):1541-1549. (Pubitemid 34621118)
37. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease. Gastroenterology. 2006;130(2):323-333.
38. Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357(3):228-238. (Pubitemid 47080387)
39. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease. Gut. 2007;56(9):1232-1239.
40. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease. Gastroenterology. 2007;132(1):52-65. (Pubitemid 46108762)
41. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease. Aliment Pharmacol Ther. 2006;23(8):1127-1136. (Pubitemid 43779352)
42. Sandborn WJ, Colombel JF, Enns R, et al; ENACT-1 Trial Group; ENACT-2 Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353(18):1912-1925. (Pubitemid 41565956)
43. Gibbons RJ, Smith S, Antman E; American College of Cardiology; American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines, I: where do they come from? Circulation. 2003;107(23):2979-2986. (Pubitemid 36736643)
44. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255-260. (Pubitemid 32729372)
45. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(5):621-630.
46. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;(3):CD000296.
47. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;(2):CD000545.
48. Travis SP, Stange EF, Lémann M, et al European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease. Gut. 2006;55(suppl 1):i16-i35. (Pubitemid 43268291)
49. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390-399.
50. Beaugerie L, Brousse N, Bouvier AM, et al CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease. Lancet. 2009;374(9701):1617-1625.
51. Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34(11-12):1318-1327.
52. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2009;7(8):874-881.
53. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab. Am J Gastroenterol. 2003;98(6):1315-1324. (Pubitemid 36741529)
54. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353(4):362-368. (Pubitemid 41132340)
55. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011;106(9):1594-1602.
56. Colombel JF, Sandborn WJ, Reinisch W, et al SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-1395.
57. Treton X, Bouhnik Y, Mary JY, et al; Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission. Clin Gastroenterol Hepatol. 2009;7(1):80-85.
58. Louis E, Mary JY, Vernier-Massouille G, et al; Groupe D'Etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63-70.
59. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929-936. (Pubitemid 351451967)
60. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130(3):650-656. (Pubitemid 43374514)
61. D'Haens G, Baert F, van Assche G, et al Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease. Lancet. 2008;371(9613):660-667. (Pubitemid 351284485)
62. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47(4):487-496.
63. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126(2):414-424. (Pubitemid 38182298)
64. McLeod RS, Wolff BG, Steinhart AH, et al. Risk and significance of endoscopic/ radiological evidence of recurrent Crohn's disease. Gastroenterology. 1997;113(6):1823-1827. (Pubitemid 27512140)
65. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27(3):220-227.
66. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370-1377.
67. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med. 2005;352(24):2499-2507. (Pubitemid 41007865)
68. Sandborn WJ, Feagan BG, Fedorak RN, et al Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135(4):1130-1141.
69. Korzenik JR. Is Crohn's disease due to defective immunity? Gut. 2007;56(1):2-5. (Pubitemid 46044879)
70. Stappenbeck TS, Rioux JD, Mizoguchi A, et al. Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy. 2011;7(4):355-374.
71. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140(6):1704-1712.
72. Canavan C, Abrams KR, Mayberry J. Colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23(8):1097-1104. (Pubitemid 43779348)
73. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143(2):375-381.
74. Farraye FA, Odze RD, Eaden J, et al AGA Institute Medical Position Panel on Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):738-745.
75. Biancone L, Michetti P, Travis S, et al European Crohn's and Colitis Organisation. European evidence-based consensus on the management of ulcerative colitis. J Crohns Colitis. 2008;2(1):63-92. (Pubitemid 351179489)
76. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update). Am J Gastroenterol. 2004;99(7):1371-1385.
77. Odes S. How expensive is inflammatory bowel disease? World J Gastroenterol. 2008;14(43):6641-6647.
78. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease. Aliment Pharmacol Ther. 2009;30(3):265-274.
79. Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? Inflamm Bowel Dis. 2013;19(1):37-44.